Taisho Pharmaceutical Holdings Co., Ltd.
TAIPY · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.54 | -0.09 | -0.00 | 0.03 |
| FCF Yield | 49.54% | 44.60% | 50.29% | 47.57% |
| EV / EBITDA | -42.74 | -30.01 | -15.24 | -35.53 |
| Quality | ||||
| ROIC | 0.21% | 0.49% | 0.76% | -0.04% |
| Gross Margin | 55.61% | 57.01% | 59.75% | 56.29% |
| Cash Conversion Ratio | 7.38 | 4.72 | 3.19 | -7.06 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.15% | 6.32% | 4.95% | 2.24% |
| Free Cash Flow Growth | 45.38% | 4.85% | 3.51% | 7.54% |
| Safety | ||||
| Net Debt / EBITDA | -52.14 | -34.87 | -17.20 | -39.99 |
| Interest Coverage | 31.26 | 117.53 | 193.04 | -4.82 |
| Efficiency | ||||
| Inventory Turnover | 0.58 | 0.56 | 0.56 | 0.60 |
| Cash Conversion Cycle | 193.22 | 198.21 | 179.94 | 164.87 |